Pulmicort (budesonide) is an inhaled corticosteroid indicated for maintenance treatment of asthma in children and adults. In some countries Pulmicort is also indicated for maintenance treatment of COPD.
Budesonide has pronounced and long lasting anti-inflammatory effects in the airways, and has a rapid systemic elimination, which results in a high therapeutic ratio. Administration via Turbuhaler, which delivers a high fraction of budesonide fine particles into the lungs, and less drug at unwanted sites, further enhances the therapeutic ratio.
Core documentation of the benefits and possible side effects of inhaled steroids has been gained through studies with Pulmicort. Once daily administration, early intervention and long-term use in children have thoroughly been documented with Pulmicort. Long term safety studies using clinically relevant doses show no influence on final height of children, nor on bone mineral density or fracture risks in adult asthma and COPD patients.
In the menu to the left you can access detailed statements about this product and review its clinical characteristics. You will also find alternative names for Pulmicort.
Please note: This website is for an international audience of respiratory health professionals. If you are in the US you should visit MySymbicort. If you are in the UK you should visit AstraZeneca UK. If you are a patient or carer please visit My Symbicort Medicine. Not all products are available in all countries. Product licenses differ between countries. Please consult your local prescribing information.
